CL2019001529A1 - Compuestos de quinona y acido ascórbico para el tratamiento de la enfermedad de chagas. - Google Patents

Compuestos de quinona y acido ascórbico para el tratamiento de la enfermedad de chagas.

Info

Publication number
CL2019001529A1
CL2019001529A1 CL2019001529A CL2019001529A CL2019001529A1 CL 2019001529 A1 CL2019001529 A1 CL 2019001529A1 CL 2019001529 A CL2019001529 A CL 2019001529A CL 2019001529 A CL2019001529 A CL 2019001529A CL 2019001529 A1 CL2019001529 A1 CL 2019001529A1
Authority
CL
Chile
Prior art keywords
ascorbic acid
quinone
chagas disease
treatment
acid compounds
Prior art date
Application number
CL2019001529A
Other languages
English (en)
Inventor
Sueli De Oliveira Silva Lautenschlager
Vânia Cristina Desoti
Celso Vataru Nakamura
Valdecir Farias Ximenes
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of CL2019001529A1 publication Critical patent/CL2019001529A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MÉTODO PARA TRATAR, PREVENIR O ALIVIAR UNO O MÁS SÍNTOMAS DE LA ENFERMEDAD DE CHAGAS EN UN SUJETO, QUE COMPRENDE ADMINISTRAR AL SUJETO: (I) ÁCIDO ASCÓRBICO, O UN SOLO ENANTIÓMERO, UNA MEZCLA DE ENANTIÓMEROS, O UNA MEZCLA DE SUS DIASTEREÓMEROS; O SU SAL, SOLVATO O HIDRATO FARMACÉUTICAMENTE ACEPTABLE; Y (II) UN COMPUESTO DE QUINONA, O UN SOLO ENANTIÓMERO, UNA MEZCLA DE ENANTIÓMEROS, O UNA MEZCLA DE SUS DIASTEREÓMEROS, O SU SAL, SOLVATO, HIDRATO O PROFÁRMACO FARMACÉUTICAMENTE ACEPTABLE.
CL2019001529A 2016-12-06 2019-06-05 Compuestos de quinona y acido ascórbico para el tratamiento de la enfermedad de chagas. CL2019001529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430758P 2016-12-06 2016-12-06

Publications (1)

Publication Number Publication Date
CL2019001529A1 true CL2019001529A1 (es) 2019-11-08

Family

ID=62491595

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001529A CL2019001529A1 (es) 2016-12-06 2019-06-05 Compuestos de quinona y acido ascórbico para el tratamiento de la enfermedad de chagas.

Country Status (10)

Country Link
US (1) US11998523B2 (es)
AR (1) AR110317A1 (es)
BR (1) BR112019011789A2 (es)
CL (1) CL2019001529A1 (es)
CO (1) CO2019007158A2 (es)
CR (1) CR20190323A (es)
EC (1) ECSP19048402A (es)
MX (2) MX2019006593A (es)
PE (1) PE20191745A1 (es)
WO (1) WO2018106623A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
US8507555B2 (en) 2006-06-16 2013-08-13 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) * 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) * 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
EP2456306A4 (en) 2009-07-20 2012-12-26 Summa Health System VITAMIN C AND VITAMIN K, AND COMPOSITIONS THEREOF FOR TREATING OESTOLYSIS OR EXTENDING A PROTEST IMPLANT
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2600855A2 (en) 2010-08-04 2013-06-12 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
EP2943188A1 (en) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamins c and k for treating polycystic diseases
ES2811674B2 (es) 2018-06-06 2024-02-07 Ic Medtech Corp Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria

Also Published As

Publication number Publication date
PE20191745A1 (es) 2019-12-12
MX2022008055A (es) 2022-07-27
US11998523B2 (en) 2024-06-04
ECSP19048402A (es) 2019-09-30
US20190343794A1 (en) 2019-11-14
CO2019007158A2 (es) 2019-10-09
CR20190323A (es) 2019-11-11
BR112019011789A2 (pt) 2019-10-29
WO2018106623A1 (en) 2018-06-14
MX2019006593A (es) 2019-09-13
AR110317A1 (es) 2019-03-20

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
CO6660497A2 (es) Derivados del ácido nft-2-ilacético para tratar el sida
BR112017018092A2 (pt) composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
UY35400A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112018006039A2 (pt) terapia adjuvante com 25-hidroxivitamina d e artigos para a mesma
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
AR101740A1 (es) Terapia de combinación y composiciones
CR20180433A (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
CL2020003143A1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.